Skip to content

Protocols

2018

MSAC Application 1534: Heritable mutations associated with familial hypercholesterolaemia. September 2018.

MSAC Application 1519: Tisagenlecleucel (CTL019) for treatment of refractory/relapsed CD19-positive leukaemia and lymphoma. May 2018.

MSAC Application 1506: Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with unresectable Stage IV urothelial cancer. February 2018.

MSAC Application 1511: Extended half-life clotting factor concetrates for the treatment of haemophilia A and B. February 2018.

MSAC Application 1508: Pembrolizumab (MK-3475) in mismatch repair deficient Stage IV solid tumours, other than colorectal cancer. February 2018.

2017

MSAC Application 1490: Breast magnetic resonance imaging (MRI) for breast implant-associated anaplastic large cell lymphoma. September 2017.

MSAC Application 1496: Micro-invasive glaucoma surgery (MIGS) device implantation (external to Schlemm's canal) in patients with mild-to-moderate primary open-angle glaucoma. April 2017.

MSAC Application 1483: Trabecular bypass micro-invasive glaucoma surgery (MIGS) device implantation in patients with mild-to-moderate primary open-angle glaucoma. April 2017.

MSAC Application 1468: SIR-Spheres(R) Y-90 resin microspheres for the treatment of hepatic metastases which are secondary to colorectal cancer and are not suitable for resection or ablation, used in combination with systemic chemotherapy. April 2017.

MSAC Application 1497: SIR-Spheres(R) Y-90 resin microspheres for the treatment of advanced primary liver cancer and liver dominant metastatic tumours other than colorectal. Withdrawn.

School of Public Health
The University of Adelaide
Address

Mail Drop 545 or 511
Level 9, Adelaide Health & Medical Sciences Building
SA  5005  AUSTRALIA

Contact

T: +61 8 8313 4617
T: +61 8 8313 3576
ahta@adelaide.edu.au

AHTA Logo